Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NTR004
MIFTS: 60

Neutropenia

Categories: Blood diseases, Rare diseases, Genetic diseases, Bone diseases, Immune diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Neutropenia

About this section

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 38 12 29 55 6 3 44 15 73
Leukopenia 73

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Blood diseases Bone diseases Immune diseases Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:1227
ICD10 33 D70 D70.9
ICD9CM 35 288.0 288.00
MeSH 44 D009503
Sources

Summaries for Neutropenia

About this section
CDC : 3 Preventing Infections in Cancer Patients is a campaign focused on providing resources that will help reduce the risk of developing potentially life-threatening infections during chemotherapy treatment.

MalaCards based summary : Neutropenia, also known as leukopenia, is related to severe congenital neutropenia autosomal dominant and neonatal alloimmune neutropenia. An important gene associated with Neutropenia is VPS13B (Vacuolar Protein Sorting 13 Homolog B), and among its related pathways/superpathways are Regulation of IFNA signaling and Immune response Role of DAP12 receptors in NK cells. The drugs Cilastatin and Imipenem have been mentioned in the context of this disorder. Affiliated tissues include lung, myeloid and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Neutropenia or neutropaenia is an abnormally low concentration of neutrophils (a type of white blood... more...

Sources

Related Diseases for Neutropenia

About this section

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Severe Congenital Neutropenia Elane-Related Neutropenia
Severe Congenital Neutropenia Autosomal Dominant

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 376)
# Related Disease Score Top Affiliating Genes
1 severe congenital neutropenia autosomal dominant 34.5 ELANE GFI1
2 neonatal alloimmune neutropenia 34.0 CD177 FCGR3B
3 cyclic neutropenia 34.0 CSF2 CSF3 ELANE IL3
4 transient neonatal neutropenia 33.9 FCGR3A FCGR3B
5 felty syndrome 33.0 CSF2 CSF3 ELANE IL3
6 severe congenital neutropenia 31.7 CSF2 CSF3 CSF3R ELANE G6PC3 GFI1
7 zygomycosis 30.9 CSF3 ELANE
8 leukemia, acute myeloid 30.2 CSF2 CSF3 CSF3R GFI1 IL3
9 pancytopenia 30.0 CSF2 CSF3 IL3
10 lymphoma, non-hodgkin, familial 29.9 CSF2 CSF3 FCGR3A IL3
11 aplastic anemia 29.8 CSF2 CSF3 CSF3R IL3
12 myelodysplastic syndrome 29.3 CSF2 CSF3 CSF3R IL3
13 dyskeratosis congenita 29.3 CSF2 CSF3 USB1
14 leukemia, chronic myeloid 29.0 CD177 CSF2 CSF3 CSF3R IL3
15 poikiloderma with neutropenia 12.5
16 neutropenia, severe congenital, 3, autosomal recessive 12.4
17 neutropenia, nonimmune chronic idiopathic, of adults 12.3
18 neutropenia, severe congenital, x-linked 12.3
19 idiopathic neutropenia 12.3
20 3-methylglutaconic aciduria with cataracts, neurologic involvement, and neutropenia 12.2
21 neutropenia, severe congenital, 5, autosomal recessive 12.2
22 neutropenia, severe congenital, 7, autosomal recessive 12.2
23 neutropenia, severe congenital, 4, autosomal recessive 12.2
24 neutropenia, severe congenital, 1, autosomal dominant 12.2
25 neutropenia, severe congenital, 2, autosomal dominant 12.2
26 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 12.2
27 neutropenia, severe congenital, 6, autosomal recessive 12.1
28 barth syndrome 12.0
29 neutropenia, chronic familial 11.9
30 elane-related neutropenia 11.9
31 neutropenia, lethal congenital, with eosinophilia 11.8
32 onychotrichodysplasia and neutropenia 11.8
33 neutropenia monocytopenia deafness 11.8
34 autosomal recessive severe congenital neutropenia due to cxcr2 deficiency 11.8
35 immunodeficiency 55 11.5
36 hermansky-pudlak syndrome 2 11.5
37 clpb deficiency 11.4
38 whim syndrome 11.4
39 leukemia, acute lymphoblastic 11.2
40 wiskott-aldrich syndrome 11.2
41 glycogen storage disease ib 11.2
42 large granular lymphocyte leukemia 11.1
43 immunodeficiency with hyper-igm, type 1 11.1
44 cohen syndrome 11.1
45 propionic acidemia 11.1
46 immunodeficiency 50 10.9
47 ablepharon-macrostomia syndrome 10.8
48 lichtenstein syndrome 10.8
49 dentin dysplasia, type i 10.7
50 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 10.7

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 50)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Chronic Kidney Failure
Colorectal Cancer Decubitus Ulcer
Deficiency Anemia Esophageal Cancer
Esophageal Candidiasis Esophagitis
Felty Syndrome Female Breast Cancer
Gastric Cancer Heart Disease
Hepatic Encephalopathy Hydronephrosis
Hypersplenism Hypothyroidism
Immune Deficiency Disease Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1
Intestinal Obstruction Iron Deficiency Anemia
Leukemia, Chronic Lymphocytic Lymphoblastic Leukemia
Main Bronchus Cancer Megakaryocytic Leukemia
Oral Candidiasis Ovarian Cancer
Paralytic Ileus Plasma Cell Neoplasm
Pneumocystosis Portal Hypertension
Postinflammatory Pulmonary Fibrosis Primary Thrombocytopenia
Protein-Energy Malnutrition Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2
Rectal Neoplasm Respiratory Failure
Retinitis Pigmentosa and Erythrocytic Microcytosis Rheumatoid Arthritis
Sideroblastic Anemia Systemic Lupus Erythematosus
Waldenstrom Macroglobulinemia Wegener Granulomatosis

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia
Sources

Symptoms & Phenotypes for Neutropenia

About this section

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.02 USB1
2 Decreased viability GR00381-A-1 10.02 JAGN1 USB1
3 Decreased viability GR00402-S-2 10.02 IL3 JAGN1 SLC37A4 TAZ UGT1A1 USB1
4 no effect GR00402-S-1 9.62 CSF2 CSF3 CSF3R ELANE FCGR3A FCGR3B

MGI Mouse Phenotypes related to Neutropenia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CSF3 CSF3R ELANE FCGR3B G6PC3 GFI1
2 immune system MP:0005387 9.4 CD177 CSF2 CSF3 CSF3R ELANE FCGR3B
Sources

Drugs & Therapeutics for Neutropenia

About this section

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 651)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilastatin Approved, Investigational Phase 4,Not Applicable 82009-34-5 5280454 6435415
2
Imipenem Approved Phase 4,Not Applicable 74431-23-5, 64221-86-9 104838
3
Meropenem Approved, Investigational Phase 4,Phase 2 119478-56-7 64778 441130
4
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
5
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
6
Ceftazidime Approved Phase 4,Phase 3,Phase 2 78439-06-2, 72558-82-8 5481173
7
Piperacillin Approved Phase 4,Phase 2,Not Applicable 66258-76-2 43672
8
Tazobactam Approved Phase 4,Phase 2,Not Applicable 89786-04-9 123630
9
Vancomycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 1404-90-6 441141 14969
10
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 3081921 477468
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
12
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 84625-61-6 55283
13
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
14
Menthol Approved Phase 4,Phase 2,Phase 1,Not Applicable 2216-51-5 16666
15
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
16
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
17
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
18
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
19
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
20
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
21
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
22
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137234-62-9 71616
23
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 498142 38904
24
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 83-43-2 6741
26
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-24-8 5755
27
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
28
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
29
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 23214-92-8 31703
30
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
31
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 58957-92-9 42890
32
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
33
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
34
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
35
Epirubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 56420-45-2 41867
36
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
37
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
38
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
39
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
40
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
41
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
42
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 82410-32-0 3454
43
Valganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 175865-60-8 64147
44
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 171228-49-2 147912
45
Teicoplanin Approved, Investigational Phase 4 61036-62-2
46
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
47
Tobramycin Approved, Investigational Phase 4,Phase 3 32986-56-4 5496 36294
48
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 468682 2826718
49
Diphenhydramine Approved, Investigational Phase 4,Phase 3,Phase 1 147-24-0, 58-73-1 3100
50
Dopamine Approved Phase 4 51-61-6, 62-31-7 681

Interventional clinical trials:

(show top 50) (show all 1346)
# Name Status NCT ID Phase Drugs
1 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO Unknown status NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
2 Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
3 Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
4 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
5 Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
6 Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg Unknown status NCT02621905 Phase 4 Sporanox;Lozanoc
7 Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients Unknown status NCT02967341 Phase 4
8 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
9 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
10 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4 N-acetylcysteine
11 Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
12 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Completed NCT02213783 Phase 4 Imipenem;Imipenem
13 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia Completed NCT02805205 Phase 4 PEG-rhG-CSF
14 A Clinical Trial of Patients With Solid Tumours Receiving Granulocyte Colony Stimulating Factor as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Docetaxel Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
15 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
16 REaCT Integrated Consent Model to Compare Two Standard of Care Regimens Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
17 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
18 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients Completed NCT01401010 Phase 4 Doripenem;doripenem
19 PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
20 Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
21 A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
22 FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
23 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
24 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants Completed NCT01086878 Phase 4 cotrimoxazole
25 Diagnosis of Septicaemia by Detection of Microbial DNA in Blood in Severe Infections Completed NCT00709358 Phase 4
26 Antifungal Use in Oncohematological Neutropenic Patients Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
27 The Tobramycin Study Completed NCT00257790 Phase 4 Tobramycin once a day
28 An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
29 Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
30 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
31 A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Completed NCT02895529 Phase 4 Itraconazole;Caspofungin
32 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
33 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
34 PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy Completed NCT02805218 Phase 4 PEG-rhG-CSF
35 PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy Completed NCT02805166 Phase 4 PEG-rhG-CSF
36 Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-â…¡ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
37 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
38 Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Completed NCT01198236 Phase 4 Itraconazole
39 Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
40 The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection) Completed NCT02622659 Phase 4 Fuganlin Oral Liquid;Xiaoer Jiebiao Oral Liquid
41 SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia Completed NCT00487448 Phase 4 Fludarabine;Cytarabine;G-CSF;Idarubicin
42 Oral Zinc Therapy for the Prevention of Mucositis Completed NCT00449592 Phase 4 Zinc;Placebo
43 Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours Completed NCT00220168 Phase 4 Irinotecan, Capecitabine
44 VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel Completed NCT01684813 Phase 4 Prasugrel.;Clopidogrel
45 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
46 A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) Completed NCT01585324 Phase 4 peginterferon alfa-2a [Pegasys];ribavirin [Copegus]
47 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
48 Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance Completed NCT00400400 Phase 4 Enteric-coated mycophenolate sodium (EC-MPS);Mycophenolate mofetil;Placebo to mycophenolate sodium;Placebo to mycophenolate mofetil
49 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
50 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Recruiting NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Neutropenia:
Hematopoietic stem cell transplantation for the treatment of genetic blood cell-related diseases
Embryonic/Adult Cultured Cells Related to Neutropenia:
Bone marrow-derived hematopoietic stem cells (family)
Umbilical cord blood-derived hematopoietic stem cells (family)

Cochrane evidence based reviews: neutropenia

Sources

Genetic Tests for Neutropenia

About this section

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 29
Sources

Anatomical Context for Neutropenia

About this section

MalaCards organs/tissues related to Neutropenia:

41
Lung, Myeloid, Bone, Neutrophil, T Cells, Prostate, Bone Marrow
Sources

Publications for Neutropenia

About this section

Articles related to Neutropenia:

(show top 50) (show all 1743)
# Title Authors Year
1
Calculated decisions: MASCC Risk Index for febrile neutropenia ( 29323859 )
2018
2
Two cases of tacrolimus-induced neutropenia: A probably under-diagnosed cause of neutropenia after solid-organ transplantation. ( 29907985 )
2018
3
Poikiloderma with neutropenia in a Tunisian patient with a novel C16orf57 gene mutation. ( 29797650 )
2018
4
Reply to "Comparison of antipseudomonal betalactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis" by Horita et al. ( 29410224 )
2018
5
Management of Patients With Febrile Neutropenia: A Teachable Moment. ( 29435575 )
2018
6
Somatic mutations and clonal hematopoiesis in congenital neutropenia. ( 29092827 )
2018
7
Tailoring antimicrobials in febrile neutropenia: using faster diagnostic and communication tools to improve treatment in the era of extensively resistant pathogens. ( 29963990 )
2018
8
Successful second hematopoietic cell transplantation in severe congenital neutropenia. ( 29076228 )
2018
9
Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. ( 29883599 )
2018
10
Febrile neutropenia with bacterial paronychia. ( 29531738 )
2018
11
Risk Factors for Microbiologically-documented Infections, Mortality and Prolonged Hospital Stay in Children with Febrile Neutropenia. ( 29941699 )
2018
12
Neutropenia ( 29939524 )
2018
13
The Infectious and Non-Infectious Etiology, Clinical Picture and Outcome of Neutropenia in Immunocompetent Hospitalized Children. ( 29319583 )
2018
14
Type 1 autoimmune hepatitis presenting with severe autoimmune neutropenia. ( 29333079 )
2018
15
Prevalence and Predictors of Invasive Fungal Infections in Children with Persistent Febrile Neutropenia Treated for Acute Leukemia - A Prospective Study. ( 29956075 )
2018
16
Neutropenia as a Complication of Tumefactive Demyelinating Disease: A Case Report. ( 29330070 )
2018
17
Comparison of antipseudomonal beta-lactams for febrile neutropenia empiric therapy: systematic review and network meta-analysis: authors' reply. ( 29427805 )
2018
18
Re-titration rates after clozapine-induced neutropenia or agranulocytosis: A case report and literature review. ( 29944418 )
2018
19
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer. ( 29970575 )
2018
20
Neutropenia among patients with adenosine deaminase deficiency. ( 29753815 )
2018
21
Insights into Mutation Effect in Three Poikiloderma with Neutropenia Patients by Transcript Analysis and Disease Evolution of Reported Patients with the Same Pathogenic Variants. ( 29770900 )
2018
22
Severe Congenital Neutropenia associated with SRP54 mutation in 22q11.2 Deletion Syndrome: Hematopoietic Stem Cell Transplantation Results in Correction of Neutropenia with Adequate Immune Reconstitution. ( 29956078 )
2018
23
Procalcitonin Guiding Antimicrobial Therapy Duration in Febrile Cancer Patients with Documented Infection or Neutropenia. ( 29348438 )
2018
24
ELANE gene mutation-induced cyclic neutropenia manifesting as recurrent fever with oral mucosal ulcer: A case report. ( 29517659 )
2018
25
Quantitative Relationship Between AUEC of Absolute Neutrophil Count and Duration of Severe Neutropenia for G-CSF in Breast Cancer Patients. ( 29392707 )
2018
26
Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. ( 29349917 )
2018
27
Matched unrelated donor transplantation in glycogen storage disease type 1b patient corrects severe neutropenia and recurrent infections. ( 29515247 )
2018
28
Identification of novel <i>MECOM</i> gene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review. ( 29572239 )
2018
29
Prevalence of Fungemia in Pediatric Patients with Febrile Neutropenia. ( 29930928 )
2018
30
Efficacy and Safety of Bi-weekly Pegfilgrastim for Dose-dense Chemotherapy-induced Neutropenia in Breast Cancer Patients. ( 29970577 )
2018
31
Antibodies to human neutrophil antigen HNA-3b implicated in cases of neonatal alloimmune neutropenia. ( 29451309 )
2018
32
Clinicohematological Profile of Febrile Neutropenia in Childhood Acute Leukemia and Utility of Serum Procalcitonin Levels in Neutropenic Patients. ( 29910543 )
2018
33
Mutations in <i>SRP54</i> gene cause severe congenital neutropenia as well as Shwachman-Diamond-like syndrome. ( 29914977 )
2018
34
Febrile Neutropenia following Parvovirus B19 Infection and Cross Anti-Kell Reaction to E. Coli in Pregnancy. ( 29925108 )
2018
35
Re-randomization increased recruitment and provided similar treatment estimates as parallel designs in trials of febrile neutropenia. ( 29428873 )
2018
36
Cost-effectiveness and Improved Parent and Provider Satisfaction With Outpatient Management of Pediatric Oncology Patients, With Low-risk Fever and Neutropenia. ( 29334532 )
2018
37
Neutropenia, hypogammaglobulinemia, and pneumonia: A case of WHIM syndrome. ( 29575308 )
2018
38
Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia. ( 29364548 )
2018
39
Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged a8Y65 years: a retrospective evaluation using Medicare claims. ( 29962268 )
2018
40
Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia. ( 29953736 )
2018
41
Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy. ( 29948238 )
2018
42
A case of severe Pembrolizumab-induced neutropenia. ( 29889673 )
2018
43
Assessment of intrafamilial clinical variability of poikiloderma with neutropenia by a 10-year follow-up of three affected siblings. ( 29753917 )
2018
44
The<i>JAK2</i>V617F mutation in isolated neutropenia. ( 29383013 )
2018
45
Pyoderma Gangrenosum Secondary to Severe Congenital Neutropenia. ( 29707446 )
2018
46
Topical application of 5-fluorouracil 5 percent cream associated with severe neutropenia: discussion of a case and review of systemic reactions after topical treatment with 5-fluorouracil. ( 29906006 )
2018
47
Novel Gene Mutation in a Chinese Boy with Severe Congenital Neutropenia. ( 29744746 )
2018
48
Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia. ( 29403286 )
2018
49
Adult-onset primary cyclic autoimmune neutropenia: a case report. ( 29405299 )
2018
50
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report. ( 29685167 )
2018
Sources

Variations for Neutropenia

About this section

ClinVar genetic disease variations for Neutropenia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh37 Chromosome 8, 100880540: 100880540
2 VPS13B NM_017890.4(VPS13B): c.11314C> T (p.Gln3772Ter) single nucleotide variant Pathogenic rs386834061 GRCh38 Chromosome 8, 99868312: 99868312
3 46;XY;t(16;20)(q23.1;p11.22) Translocation Uncertain significance
4 46;XX;inv(2)(q13q14.2) inversion Uncertain significance
5 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh37 Chromosome 8, 100523652: 100523652
6 VPS13B NM_017890.4(VPS13B): c.4620delA (p.Ser1541Profs) deletion Pathogenic rs1057518939 GRCh38 Chromosome 8, 99511424: 99511424
Sources

Expression for Neutropenia

About this section
Search GEO for disease gene expression data for Neutropenia.
Sources

Pathways for Neutropenia

About this section

Pathways related to Neutropenia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Regulation of IFNA signaling 66
Show member pathways
 12.26 CSF2 CSF3 CSF3R IL3
2
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.13 CSF2 FCGR3A FCGR3B IL3 WAS
3
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.52 CSF2 CSF3 CSF3R IL3
4
Hematopoietic Stem Cell Differentiation 1
11.18 CSF2 CSF3 IL3
5
Hematopoietic cell lineage 37
10.91 CSF2 CSF3 CSF3R IL3
6
Cytokines and Inflammatory Response 1
10.61 CSF2 CSF3 IL3
Sources

GO Terms for Neutropenia

About this section

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 CSF2 CSF3 CSF3R IL3
2 cellular response to lipopolysaccharide GO:0071222 9.63 CSF2 CSF3 GFI1
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.54 CSF3 HAX1 IL3
4 immune response GO:0006955 9.43 CSF2 CSF3 FCGR3A FCGR3B IL3 WAS
5 positive regulation of actin cytoskeleton reorganization GO:2000251 9.4 CSF3 HAX1
6 regulation of myeloid cell differentiation GO:0045637 9.32 CSF2 CSF3R
7 neutrophil migration GO:1990266 9.26 CD177 JAGN1
8 glucose-6-phosphate transport GO:0015760 9.16 G6PC3 SLC37A4
9 neutrophil differentiation GO:0030223 8.8 CSF2 CSF3 JAGN1

Molecular functions related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 IgG binding GO:0019864 8.62 FCGR3A FCGR3B
Sources

Sources for Neutropenia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31